Skip to main content
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
Published Web Location
http://europepmc.org/articles/PMC3749576?pdf=renderNo data is associated with this publication.
Abstract
Background: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer. Met
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.